📊 MDLN Key Takeaways
Is MDLN a Good Investment? Thesis Analysis
Medline demonstrates solid fundamental strength with robust revenue growth of 11.5% YoY and consistent profitability generation, evidenced by 4.1% net margin and $1.3B free cash flow. The company maintains healthy liquidity (4.29x current ratio) and manageable leverage despite elevated debt levels, positioning it well for operational resilience and capital deployment.
Why Buy MDLN? Key Strengths
- Strong revenue growth of 11.5% YoY in large-cap healthcare distribution
- Healthy free cash flow generation of $1.3B with 4.6% FCF margin demonstrates operational efficiency
- Excellent liquidity position with 4.29x current ratio and $1.9B cash balance provides financial flexibility
- Consistent profitability across margins with 26.4% gross margin indicating strong pricing power or cost management
MDLN Investment Risks to Consider
- Leverage elevated at 1.16x debt-to-equity with $12.5B long-term debt relative to $10.7B equity, limiting financial flexibility
- Net income growth of only 0.5% YoY significantly lags revenue growth of 11.5%, suggesting margin compression or rising costs
- Low ROE of 10.8% and ROA of 3.0% indicate suboptimal capital efficiency relative to asset base of $38.5B
- Operating margin of 7.8% appears modest for a healthcare distribution platform, suggesting competitive pressure or operational challenges
Key Metrics to Watch
- Net income growth trajectory and margin expansion/compression in coming quarters
- Debt reduction progress and debt-to-equity ratio trending toward lower leverage
- Operating cash flow sustainability and capital expenditure requirements for growth
MDLN Financial Metrics
💡 AI Analyst Insight
The relatively thin 4.6% FCF margin may limit capital allocation flexibility. Strong liquidity with a 4.29x current ratio provides a solid financial cushion.
MDLN Profitability Ratios
MDLN vs Healthcare Sector
How Medline Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is MDLN Overvalued or Undervalued?
Based on fundamental analysis, Medline Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
MDLN Balance Sheet & Liquidity
MDLN 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Medline Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.01 indicates the company is currently unprofitable.
MDLN Growth Metrics (YoY)
MDLN Capital Allocation
MDLN SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Medline Inc. (CIK: 0002046386)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MDLN
What is the AI rating for MDLN?
Medline Inc. (MDLN) has an AI rating of BUY with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are MDLN's key strengths?
Claude: Strong revenue growth of 11.5% YoY in large-cap healthcare distribution. Healthy free cash flow generation of $1.3B with 4.6% FCF margin demonstrates operational efficiency.
What are the risks of investing in MDLN?
Claude: Leverage elevated at 1.16x debt-to-equity with $12.5B long-term debt relative to $10.7B equity, limiting financial flexibility. Net income growth of only 0.5% YoY significantly lags revenue growth of 11.5%, suggesting margin compression or rising costs.
What is MDLN's revenue and growth?
Medline Inc. reported revenue of $28.4B.
Does MDLN pay dividends?
Medline Inc. does not currently pay dividends.
Where can I find MDLN SEC filings?
Official SEC filings for Medline Inc. (CIK: 0002046386) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MDLN's EPS?
Medline Inc. has a diluted EPS of $-0.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MDLN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Medline Inc. has a BUY rating with 72% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is MDLN stock overvalued or undervalued?
Valuation metrics for MDLN: ROE of 10.8% (sector avg: 15%), net margin of 4.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MDLN stock in 2026?
Our dual AI analysis gives Medline Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MDLN's free cash flow?
Medline Inc.'s operating cash flow is $1.7B, with capital expenditures of $447.0M. FCF margin is 4.6%.
How does MDLN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 4.1% (avg: 12%), ROE 10.8% (avg: 15%), current ratio 4.29 (avg: 2).